share_log

研报掘金|中金:下调中生制药目标价至4.2港元 维持“跑赢行业”评级

Research Nuggets | CICC: Lowering the target price of Zhongsheng Pharmaceuticals to HK$4.2 to maintain “outperforming the industry” rating

Gelonghui Finance ·  Apr 6 22:40

CICC published a report saying that Zhongsheng Pharmaceutical's continued business performance last year was in line with expectations. Although revenue from the oncology business declined, revenue from other businesses increased by units. At the same time, the company entered an innovative harvest period. The company expects innovative products to account for 43% and 47% of revenue this year and next, respectively. CICC said that due to the divestment of non-core assets by Zhongsheng Pharmaceuticals, the adjusted earnings forecast per share was lowered by 14% to $0.15 for this year, the forecast for next year was 0.17 yuan, and the target price was lowered 7% to HK$4.2, maintaining the “outperforming industry” rating.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment